OUR STRENGTHS
We have a relentless focus on improving diabetes care
We believe that better technology leads to better therapy. Since our founding 20 years ago, WaveForm Diabetes has developed and delivered first-in-class glucose monitoring devices that improve the lives of people with diabetes while meeting stringent ISO and FDA guidelines.
Patented Technology
With 224 issued patents, we have extensive expertise in glucose sensor technology and extended wear adhesives.
High Quality
We utilize world-class manufacturing techniques that help us achieve accurate and reliable product performance while maximizing yields.
Patient Choice
We uniquely offer a suite of connected BGM and CGM solutions between our WaveForm Diabetes subsidiaries.
Our Partners
Enhancing our expertise and reach through partnerships
A. Menarini Diagnostics S.r.l., a leading European-based diagnostics company, partnered with WaveForm Technologies in 2019 to commercialize the WaveForm CGM in Europe and Latin America.
The innovative WaveForm CGM was specifically chosen to integrate with Menarini’s connected diabetes care platform, offering patients 14-day wear and the convenience of a smartphone-based connection. The CGM launched in select countries in Europe in 2020, under the GlucoMen brand.
WaveForm and Menarini continue to partner in testing additional CGM features and expanding into additional markets.
As we expand our diabetes business, we seek to offer innovative products that reach a broader patient base with more powerful and useful tools for diabetes management. We chose to work with WaveForm Technologies because of their technical experience, history of quality, and innovation.
By partnering with WaveForm Technologies on a Continuous Glucose Monitoring solution, we have found the patient feedback to be overwhelmingly positive, helping people to gain better control in their diabetes management.
Bayer, the global life science enterprise, and WaveForm Technologies recently entered a commercial agreement to provide CGM solutions to help address unmet needs for patients in China.
Under the new partnership, WaveForm will develop a 15-day wear CGM while Bayer will be responsible for the commercialization, distribution, sales, and customer support in mainland China.
WaveForm and Bayer will explore customized enhancements to the CGM to meet the needs of Chinese patients and physicians.
Bayer is committed to providing solutions in diabetes management in China through its expertise and a portfolio of well-established brands. The partnership with WaveForm will extend our efforts across overall diabetes management (ranging from glucose monitoring, prevention and treatment of diabetes to tackling complications); better addressing the unmet medical needs of Chinese patients and thereby helping to improve their quality of life.
AgaMatrix Holdings Announces Corporate Name Change and New CEO Rick Valencia, and Bayer Commercial Partnership in China
Read ArticleWaveForm Technologies, Inc Awarded CE Mark Approval for Their CGM System
Read ArticleWaveForm Technologies and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of CGM Solutions
Read ArticleInterested in learning more about WaveForm Diabetes?
Get in touch to learn about our products, company, and more.
Contact Us